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Abstract
Background: The obesity and lipid metabolism were previously proposed to be related with the clinical outcomes
of metastatic renal cell carcinoma (mRCC). We tried to investigate the relationship between preoperative cholesterol
level (PCL) and survival outcomes in patients with mRCC.
Methods: We analysed the data of 244 patients initially treated with cyto-reductive nephrectomy after being
diagnosed with mRCC. Patients were stratified into two groups according to the PCL cut-off level of 170 mg/dL.
The postoperative survival rates were compared using Kaplan-Meier analysis and the possible predictors of patients’
cancer-specific survival (CSS) and overall survival (OS) were tested using multivariate Cox-proportional hazard models.
Results: The low cholesterol group showed significantly worse postoperative CSS (p = 0.013) and OS (p = 0.009) than the
high cholesterol group. On multivariate analysis, low PCL was revealed as an independent predictor of worse CSS (hazard
ratio [HR], 2.162; 95% CI, 1.221–3.829; p = 0.008) and OS (HR, 2.013; 95% CI, 1.206–3.361; p = 0.007). Subsequent subgroup
analysis showed that these results were maintained in the clear cell subgroup but not in the non-clear cell subgroup.
Conclusion: Decreased PCL was significantly correlated with worse survival outcomes in patients with mRCC treated with
cytoreductive nephrectomy. The underlined mechanism is still uncharted and requires further investigation.
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Background
Renal cell carcinoma (RCC) is the most frequently
diagnosed renal malignancy [1]. Owing to the constant
advances of modern imaging technologies, the percentage
of incidentally detected renal tumours has constantly in-
creased during the last couple of decades [2, 3]. Although
those phenomena brought the overall stage downward
migration, a good percentage of patients are still diag-
nosed with metastatic renal cell carcinoma (mRCC) [3].
The use of cytoreductive nephrectomy in these patients
with mRCC was reported to have significant survival
benefits in several studies [4]. Therefore, further
understanding of prognostic biomarkers is becoming
more clinically important in selecting adequate candidates
for adjuvant or neoadjuvant therapies for patients with
mRCC perioperatively.
Several studies have reported a significant inverse
relationship between obesity and RCC prognosis [5–7].
Although obesity is a well-known risk factor for the
development of RCC [7], most studies reported that obese
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patients show more favourable pathology and survival
outcomes, a phenomenon known as the “obesity paradox”
[5, 6]. A large multicentre study recently analysed a large
multi-institutional database of patients with mRCC and
showed that patients with a low body mass index (BMI)
showed significant worse survival compared to those with a
high BMI [6]. They also showed that the high fatty acid
synthase (FAS) expression was observed in patients with
low BMI was connected to the worse survival outcomes.
Their results suggest that the lipid metabolism is one of the
important tumour metabolic mechanisms that are essential
to tumour survival and progression. Since cholesterol is an
essential cellular component that plays a crucial role in lipid
metabolism, preoperative serum cholesterol level (PCL)
may have significant correlation with prognosis in RCC
patients [8]. Unfortunately, only two studies investigated
this subject, both of which included small samples of
patients with localized RCC but none with mRCC.
Therefore, here we aimed to investigate the possible
associations of PLC with survival outcomes in patients with
mRCC after cytoreductive nephrectomy.
Methods
We retrospectively analysed the data of 281 patients diag-
nosed with mRCC and initially treated with nephrectomy
at multiple centres of South Korea. The informed consent
has been waived by an approval of our institutional ethical
review boards due to retrospective design (IRB number: B-
1702/384–102). After the exclusion of 37 patients (neoadju-
vant therapy [n = 7], other malignancy [n = 13], incomplete
information [n = 17]), we finally included 244 patients. The
clinical and pathological information was retrieved from
prospectively managed databases of each institution. Every
patient was initially evaluated using chest computed tomog-
raphy (CT) (or simple radiography), abdominal CT, and
bone scan. The PCL was included in the routine chemistry
panels which was performed as a part of preoperative
anesthetic risk evaluation within 4 weeks preceding the sur-
gery. If there were multiple measurements before the surgi-
cal treatment, mean values were regarded as representative.
Pathological stage and histological subtype were deter-
mined according to the seventh TNM classification from
the American Joint Committee Cancer Guidelines and the
Heidelberg recommendations [9, 10]. The nuclear grades of
the tumour cells were evaluated according to Fuhrman’s
grading system [11]. The survival data and cause of death
were determined by a rigorous review of the Korean
National Statistical Office’s database and medical records of
each hospital. The follow-up protocols varied slightly
among institutions or physicians but usually included
3 month intervals after surgery. The receiver operating
curve of PCL on the cancer-specific mortality was analysed
and the area under the curve was 0.598. Since a PCL of
170 mg/dL showed the maximal Youden index value, the
cut-off value was set at 170 mg/dL (Fig. 1). Therefore, the
subjects with values ≥170 mg/dL were regarded the high
PCL group and the others (PCL < 170 mg/dL) were
regarded the low PCL group.
Independent T and chi-square tests were performed to
compare the clinicopathological characteristics of the
high and low PCL groups. To compare the survival out-
comes of the two subgroups, Kaplan–Meier analyses
were performed. Using multivariate Cox-proportional
hazard models, the possible predictors of overall survival
(OS), and cancer-specific survival (CSS) were tested. All
of the statistical analyses were performed using SPSS
software (version 19.0; SPSS, Chicago, IL, USA). All of
the p values were two-sided and those <0.05 were con-
sidered statistically significant.
Results
The clinical and pathological profiles of the entire cohort
and subgroups according to the PCL are summarized in
Table 1. The median age was 59.0 years (interquartile
range [IQR], 52.0–68.0); median tumour diameter was
8.0 cm (IQR, 5.6–10.5), median PCL was 156.0 (IQR,
132.3–173.8), and median follow-up time was 13.0 months
(IQR, 6.0–26.5). There were 88 patients in the high PCL
group and 156 patients in the low PCL group. The low
PCL group showed significantly lower haemoglobin level
(p < 0.001) and higher platelet level (p = 0.038) than the
high PCL group, but no significant differences were noted
in the other clinical characteristics or pathological out-
comes between the two groups.
After a median follow-up of 12.0 months (IQR, 7.0–23.0),
85 patients died because of RCC. A total of 101 all-cause
mortalities occurred after a median follow-up of 13.0 months
(IQR, 7.0–23.5). The low PCL group showed significantly
worse CSS (p = 0.013) and OS (p = 0.009) than the high
Fig. 1 The receiver operating curve of preoperative cholesterol level
upon cancer-specific mortality (Vertical black line indicates the points
with maximal Youden’s value)
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PCL group (Fig. 2). The results from univariate Cox propor-
tional analyses on CSS and OS were summarized in Table 2.
Multivariate Cox proportional analysis revealed that low
PCL was the independent predictor for worse CSS (HR,
2.162; 95% CI, 1.221–3.829; p = 0.008) and OS (HR, 2.013;
95% CI, 1.206–3.361; p = 0.007) (Table 3). When we strati-
fied the patients by tumour histology (clear cell versus non-
clear cell types), low PCL was revealed as an independent
predictor for worse CSS (HR, 2.312; 95% CI, 1.274–4.193;
p = 0.006) and OS (HR, 2.204; 95% CI, 1.279–3.799;
Table 1 Summarization of clinico-pathologic factors of entire patients and according to the subgroups stratified by the cholesterol








Median (IQR) or Number (percent)
Age (y) 59.0 (52.0–68.0) 57.5 (52.0–67.0) 60.0 (51.3–68.8) 0.981
BMI (kg/m2) 23.0 (21.0–24.8) 23.5 (21.8–42.8) 22.9 (20.8–24.9) 0.239
Sex (male) 185 (75.8%) 50 (69.4%) 135 (78.5%) 0.091
Serum Albumin (g/dL) 4.0 (3.5–4.3) 4.3 (3.9–4.4) 3.9 (3.4–4.2) < 0.001
Hemoglobin (g/dL) 12.1 (10.6–13.6) 13.1 (11.7–14.7) 11.8 (10.3–13.1) < 0.001
Platelet (k/dL) 274.5 (132.3–173.8) 271.5 (212.5–320.5) 299.8 (222.0–378.8) 0.038
PLC (mg/dL) 156.0 (132.3–173.8) 190 (178–205.8) 139.1 (126.3–157.8)
Corrected calcium (mg/dL) 9.2 (8.9–9.7) 9.4 (9.0–9.8) 9.5 (8.8–9.6)
ECOG score (≥2) 79 (32.4%) 22 (30.6%) 57 (33.1%) 0.765
Diabetes mellitus 60 (24.7%) 14 (19.7%) 46 (26.7%) 0.326
Hypertension 120 (49.6%) 33 (46.5%) 87 (50.9%) 0.574
Tumor size (cm) 8.0 (5.6–10.5) 6.5 (5.0–9.5) 8.7 (6.1–11.0) 0.407
Clinical stage (≥3) 138 (56.6%) 32 (44.4%) 106 (61.6%) 0.059
Metastatic sites 0.541
Lung 78 (32.0%) 23 (31.9%) 55 (32.0%)
Liver 7 (2.7%) 1 (1.4%) 5 (2.9%)
Bone 24 (9.8%) 10 (13.9%) 14 (8.1%)
Non-regional LNI 2 (1.0%) 0 (0%) 2 (1.2%)
Adrenal gland 8 (3.3%) 4 (5.6%) 4 (2.3%)
Multiple metastasis 10 (4.1%) 3 (4.2%) 7 (4.1%)
Information missing 108 (44.3%) 33 (45.8%) 75 (43.6%)
Miscellaneous 2 (1.0%) 0 (0%) 2 (1.2%)
Pathologic stage 0.060
pT1 60 (24.6%) 24 (33.3%) 36 (20.9%)
pT2 36 (14.8%) 11 (15.3%) 25 (14.5%)
pT3 117 (48.0%) 33 (45.8%) 84 (48.8%)
pT4 31 (12.7%) 4 (5.6%) 27 (15.7%)
Fuhrman grade 0.424
≤ 2 34 (13.9%) 12 (16.7%) 22 (12.8%)
≥ 3 210 (86.1%) 60 (83.3%) 150 (87.2%)
Histologic subtype 0.214
Clear cell 213 (87.3%) 67 (93.1%) 146 (84.9%)
Papillary 13 (5.3%) 2 (2.8%) 11 (6.4%)
Chromophobe 4 (1.6%) 0 (0%) 4 (2.3%)
Collecting duct 5 (2.0%) 1 (1.4%) 4 (2.3%)
Unclassified 9 (3.7%) 2 (2.8%) 7 (4.1%)
IQR interquartile range, PCL preoperative cholesterol level, BMI body mass index, ECOG Eastern Cooperative Oncology Group, LNI lymph node invasion
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p = 0.004) in the clear cell subgroup (Table 4). However,
there were no significant relationships between PCL
and survival outcomes in the non-clear cell subgroup
(all p values >0.05). Subsequently, we further stratified the
entire patient cohort into three risk groups (favourable,
intermediate, poor) according to Heng’s model. We ob-
served worse survival outcomes in the low PCL group,
but the results did not reach statistical significance due to
the small number of subjects (Table 4).
Discussion
In the present study, we found that low PCL was independ-
ently correlated with worse survival outcomes in mRCC
patients treated by cytoreductive nephrectomy. Interest-
ingly, PCL showed significant results in the clear cell type
RCC but not in the non-clear cell RCC, which implies that
lipid metabolism is mainly associated with clear cell subtype
RCC. The PCL showed high HR in all three risk groups
according to Heng’s criteria, although the results were non-
significant due to the small number of included subjects.
Malignant cells have the notable feature of invasiveness
and relentless proliferation, both of which require
profound energy and raw materials. To support those
abilities, most cancer cells have special metabolisms that
enable them to promote their survival. This phenomenon
has been termed “metabolic transformation” [12]. Among
those, the most well-known metabolism in cancer cells is
the “Warburg effect” [13]. Warburg et al. found that can-
cer cells produced adenosine triphosphate by non-aerobic
glycolysis even in circumstances of sufficient oxygen, and
this peculiar metabolism is beneficial because it produces
less reactive oxygen species, which are hazardous to can-
cer cells due to the oxidative stress. Along with glucose
metabolism, lipid metabolism is crucial to maintaining
cancer proliferation and finishing the new building blocks
because proliferating cells require plenty of nucleotides,
fatty acids, membrane lipids, and proteins. Many cancer
cells show high rates of de novo lipid synthesis [14].
Since cholesterol is an essential component of cellular
membranes and important in energy production of tumour
Fig. 2 Kaplan-Meier analyses of cancer-specific survival (a) and overall survival (b) by preoperative cholesterol level
Table 2 Univariate Cox regression model adjusted for possible predictors estimating cancer-specific and overall survival in 244
patients treated with cyto-reductive nephrectomy for metastatic renal cell carcinoma
Cancer-specific survival Overall survival
HR 95% CI of HR p value HR 95% CI of HR p value
Age 1.004 0.986–1.023 0.679 1.005 0.989–1.023 0.530
BMI (kg/m2) Reference (< 20) Reference (< 20)
20–25 0.778 0.456–1.327 0.356 0.783 0.478–1.283 0.332
≥ 25 0.373 0.182–0.762 0.007 0.387 0.202–0.743 0.004
Albumin (g/dL) Reference (< 3.5) Reference (< 3.5)
3.5–4.3 0.610 0.375–0.991 0.046 0.577 0.371–0.899 0.015
≥ 4.3 0.515 0.290–0.916 0.024 0.485 0.286–0.822 0.007
Heng’s criteria Reference (Low risk) Reference (Low risk)
Intermediate risk 1.265 0.729–2.198 0.403 1.188 0.720–1.961 0.499
High risk 1.842 0.957–3.546 0.067 1.806 0.999–3.266 0.050
Cholesterol level (cat.) 2.251 1.285–3.941 0.005 2.100 1.272–3.466 0.004
HR hazard ratio, CI confidence interval, BMI body mass index, cat. Categorical variable
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survival, the several previous studies investigated the rela-
tionship between cholesterol level and cancer development
[15–17]. A large epidemiologic study analysed 33,368 Japa-
nese subjects and concluded the presence of an increased
incidence of stomach and liver cancers in patients having
low cholesterol levels [15]. Another prospective study by
Asano et al. also demonstrated that there were inverse asso-
ciation between cholesterol level and gastric cancer inci-
dence after analysing the data of 2604 subjects for 14 years
follow-up [16]. Kitahara et al. recently performed a retro-
spective analysis of a large database from South Korea with
1 million subjects and concluded that cholesterol level was
Table 3 Multivariate Cox regression model adjusted for possible predictors estimating cancer-specific and overall survival in 244
patients treated with cyto-reductive nephrectomy for metastatic renal cell carcinoma
Cancer-specific survival Overall survival
HR 95% CI of HR p value HR 95% CI of HR p value
Age 1.002 0.983–1.021 0.865 1.003 0.986–1.021 0.713
BMI (kg/m2) Reference (< 20) Reference (< 20)
20–25 0.792 0.459–1.369 0.404 0.805 0.485–1.336 0.402
≥ 25 0.443 0.202–0.924 0.030 0.466 0.232–0.936 0.032
Albumin (g/dL) Reference (< 3.5) Reference (< 3.5)
3.5–4.3 0.776 0.440–1.370 0.382 0.716 0.426–1.204 0.208
≥ 4.3 0.784 0.399–1.544 0.482 0.713 0.383–1.328 0.287
Heng’s criteria Reference (Low risk) Reference (Low risk)
Intermediate risk 1.095 0.623–1.926 0.752 1.033 0.619–1.725 0.902
High risk 1.185 0.550–2.553 0.664 1.132 0.565–2.270 0.727
Cholesterol level (cat.) 2.162 1.221–3.829 0.008 2.013 1.206–3.361 0.007
Age 1.002 0.983–1.021 0.830 1.003 0.986–1.021 0.701
BMI (kg/m2) Reference (< 20) Reference (< 20)
20–25 0.827 0.479–1.430 0.497 0.857 0.517–1.420 0.549
≥ 25 0.462 0.214–0.997 0.049 0.503 0.249–1.017 0.056
Albumin (g/dL) Reference (< 3.5) Reference (< 3.5)
3.5–4.3 0.882 0.498–1.561 0.665 0.789 0.468–1.327 0.371
≥ 4.3 0.892 0.437–1.821 0.753 0.769 0.401–1.473 0.428
Heng’s criteria Reference (Low risk) Reference (Low risk)
Intermediate 1.060 0.601–1.870 0.840 1.024 0.613–1.712 0.927
High risk 1.235 0.576–2.649 0.588 1.193 0.596–2.389 0.618
Cholesterol level (con.) 0.993 0.987–0.999 0.032 0.995 0.989–1.000 0.063
HR hazard ratio, CI confidence interval, BMI body mass index, con. Continuous variable, cat. Categorical variable
Table 4 Multivariate Cox hazard ratio models for the impact of low cholesterol on cancer-specific and overall survival after surgical
treatment of metastatic renal cell carcinoma
Cancer-specific survival Overall survival
HR 95% CI of HR p-value HR 95% CI of HR p-value
Entire cohorts 2.162 1.221–3.829 0.008 2.013 1.206–3.361 0.007
Subgroups according to the tumor histology
Clear cell histology 2.312 1.274–4.193 0.006 2.204 1.279–3.799 0.004
Other histology 0.767 0.076–7.771 0.822 0.285 0.043–1.879 0.192
Subgroups according to the Heng’s model
Favorable risk 1.556 0.487–4.967 0.455 1.767 0.602–5.185 0.300
Intermediate 1.809 0.907–3.611 0.093 1.583 0.851–2.947 0.147
Poor 1.538 0.339–6.972 0.577 1.735 0.406–7.416 0.457
Multivariate analyses were adjusted for age, body mass index, Heng’s risk group, preoperative albumin and cholesterol level. HR hazard ratio, CI
confidence interval
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correlated with increased incidence of several malignancies
[17]. However, the influence of cholesterol was quite het-
erogeneous between the different malignancies. From their
results, prostate, colon, and breast cancer showed high inci-
dences in patients with high cholesterol, whereas liver,
stomach, and lung cancer showed high incidences in pa-
tients with low cholesterol, showing that the relationship is
quite variable and cancer-specific. Apart from the increased
incidences, little has been investigated about the relation-
ship between cholesterol level and cancer prognosis. Ohno
et al. analysed 364 clear cell RCC patients and reported that
a high PCL was associated with better CSS, although the
findings of their multivariate analysis were not statistically
significant due to a small number of subjects [18]. Another
study by Martino et al. analysed a larger cohort of 867 sub-
jects with localized RCC and concluded that low PCL inde-
pendently correlated with worse CSS [19]. To our best
knowledge, our study is the first to evaluate the prognostic
value of PCL in patients with mRCC.
As the terminology “clear cell” indicates, the clear cell
type of RCC accumulates significant amounts of choles-
terol ester and glycogen in the cytosol [20]. Furthermore,
several genes involved in lipid metabolism were previ-
ously reported to be related with clear cell type RCC
progression [21]. In the present study, PCL showed sig-
nificant associations in clear cell subtypes but not in
non-clear cell subtypes, which implicates these relation-
ship is intact only in the clear cell subtype. However, the
exact mechanism or pathways underneath these phe-
nomena are obscure and require elucidation.
Our study has several important limitations. First, the
retrospective design and information gathering method
are not immune to recall bias. Second, we could not
analyse the influence of specific drugs such as statins.
Third, patients received different salvage or palliative
therapies from different attending physicians. Finally, we
included only mRCC patients treated with nephrectomy,
and further studies are needed to confirm our findings
in all patients with mRCC.
Conclusion
Preoperative serum cholesterol level was associated with
worse survival outcomes in patients with mRCC after
treatment with cytoreductive nephrectomy. Further basic
studies are needed to elucidate the exact lipid metabol-
ism underlying this peculiar phenomenon.
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